Connacht Asset Management’s Zimmer Biomet ZBH Stock Holding History

Connacht Asset Management’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,122	Closed	-$728K	–	130
2021 Q3	$728K	Sell	5,122 -2,068	-29%	-$304K	0.47%	54
2021 Q2	$1.12M	Buy	+7,190	New	+$1.16M	0.48%	67

Other funds holding ZBH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Connacht Asset Management's ZBH Position: Q4 2021 in Review

Connacht Asset Management sold out of Zimmer Biomet (ZBH) in Q4 2021, closing a stake of 5,122 shares — an estimated $728K sold.

Connacht Asset Management first reported a position in ZBH in Q2 2021 and held it in 2 quarters. The position peaked at $1.12M in Q2 2021. 998 funds tracked by Wall St. Rank hold ZBH as of Q4 2021.

Connacht Asset Management reported no remaining Zimmer Biomet position as of Q4 2021 after selling out during the quarter.
Connacht Asset Management sold 5,122 Zimmer Biomet shares in Q4 2021, an estimated $728K.
Connacht Asset Management first reported a position in Zimmer Biomet in Q2 2021 and held it in 2 quarters.
Connacht Asset Management's Zimmer Biomet position peaked at $1.12M in Q2 2021.
998 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2021.

Based on Connacht Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.